NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free tsvt Stock Alerts $4.96 +0.01 (+0.20%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$4.93▼$5.1050-Day Range$3.96▼$5.9652-Week Range$1.53▼$12.69Volume363,320 shsAverage Volume1.32 million shsMarket Capitalization$254.94 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 2seventy bio alerts: Email Address 2seventy bio MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside165.5% Upside$13.17 Price TargetShort InterestBearish13.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$3.14 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.39) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector397th out of 903 stocksPharmaceutical Preparations Industry178th out of 420 stocks 3.2 Analyst's Opinion Consensus Rating2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst Coverage2seventy bio has only been the subject of 2 research reports in the past 90 days.Read more about 2seventy bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.60% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in 2seventy bio has recently decreased by 4.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSVT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for 2seventy bio this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for TSVT on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows5 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,143,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 2seventy bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($1.39) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 2seventy bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About 2seventy bio Stock (NASDAQ:TSVT)2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More TSVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSVT Stock News HeadlinesMay 3, 2024 | finance.yahoo.com2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024May 3, 2024 | businesswire.com2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024May 7, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 29, 2024 | americanbankingnews.com2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Hold" from AnalystsApril 17, 2024 | msn.com2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's WhyApril 13, 2024 | morningstar.com2seventy bio Inc Ordinary SharesApril 10, 2024 | investing.comCiti raises 2Seventy Bio stock target on FDA approvalApril 8, 2024 | markets.businessinsider.comPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive DynamicsMay 7, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 7, 2024 | markets.businessinsider.comBuy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic OutlookApril 5, 2024 | msn.comBristol Myers Wins FDA Nod for AbecmaApril 5, 2024 | msn.comFDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerApril 5, 2024 | seekingalpha.comBristol Myers, 2seventy bio's Abecma approved for earlier line multiple myelomaApril 5, 2024 | finance.yahoo.comU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyMarch 20, 2024 | msn.com2seventy bio appoints Eli Casdin and Charles Newton to its board of directorsMarch 20, 2024 | businesswire.com2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsMarch 20, 2024 | morningstar.comThinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?March 17, 2024 | marketwatch.comBristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee ApprovalMarch 16, 2024 | msn.comBristol Myers wins FDA AdCom backing for Abecma label expansionMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)March 14, 2024 | marketwatch.com2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene TherapyMarch 7, 2024 | seekingalpha.com2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.com2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial OutlookMarch 7, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near TermMarch 6, 2024 | finance.yahoo.comWhen Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?March 5, 2024 | investorplace.comTSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023See More Headlines Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/07/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TSVT CUSIPN/A CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees274Year FoundedN/APrice Target and Rating Average Stock Price Target$13.17 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+165.5%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-216.73% Pretax Margin-216.73% Return on Equity-59.19% Return on Assets-29.67% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio3.98 Sales & Book Value Annual Sales$100.39 million Price / Sales2.54 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.98Miscellaneous Outstanding Shares51,400,000Free Float50,068,000Market Cap$254.94 million OptionableOptionable Beta1.87 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Nick Leschly (Age 51)President & Chairman of the Board Comp: $1.81MMr. William D. Baird III (Age 52)M.B.A., CEO & Director Comp: $810.83kVicki EatwellChief Financial OfficerJessica SnowSenior VP of Quality and Head of OperationsMichael CertoVP & Head of Genome EditingAnna Truppel-HartmannChief Medical OfficerMore ExecutivesKey CompetitorsAldeyra TherapeuticsNASDAQ:ALDXXBiotechNASDAQ:XBITFoghorn TherapeuticsNASDAQ:FHTXImmutepNASDAQ:IMMPRenovaroNASDAQ:RENBView All CompetitorsInsiders & InstitutionsSusquehanna Fundamental Investments LLCBought 138,243 shares on 5/7/2024Ownership: 0.269%SG Americas Securities LLCSold 9,874 shares on 5/7/2024Ownership: 0.034%Wedmont Private CapitalBought 85,934 shares on 4/10/2024Ownership: 0.167%Casdin Capital, LlcBought 330,000 shares on 3/25/2024Total: $1.67 M ($5.07/share)Casdin Capital, LlcBought 300,000 shares on 3/21/2024Total: $1.47 M ($4.90/share)View All Insider TransactionsView All Institutional Transactions TSVT Stock Analysis - Frequently Asked Questions Should I buy or sell 2seventy bio stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. View TSVT analyst ratings or view top-rated stocks. What is 2seventy bio's stock price target for 2024? 8 brokerages have issued 1-year target prices for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they expect the company's share price to reach $13.17 in the next year. This suggests a possible upside of 165.5% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts. How have TSVT shares performed in 2024? 2seventy bio's stock was trading at $4.27 at the start of the year. Since then, TSVT stock has increased by 16.2% and is now trading at $4.96. View the best growth stocks for 2024 here. Are investors shorting 2seventy bio? 2seventy bio saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average trading volume of 1,450,000 shares, the short-interest ratio is presently 4.7 days. Approximately 14.3% of the company's stock are sold short. View 2seventy bio's Short Interest. When is 2seventy bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TSVT earnings forecast. How can I listen to 2seventy bio's earnings call? 2seventy bio will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) released its earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The company had revenue of $10.68 million for the quarter, compared to the consensus estimate of $13.91 million. 2seventy bio had a negative net margin of 216.73% and a negative trailing twelve-month return on equity of 59.19%. During the same period last year, the company posted ($0.60) earnings per share. What ETFs hold 2seventy bio's stock? ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM). Who are 2seventy bio's major shareholders? 2seventy bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Susquehanna Fundamental Investments LLC (0.27%), Wedmont Private Capital (0.17%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSVT) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyObama’s Forever Term [exposed]Porter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
